Tod Smeal - Cardiff Oncology Chief Officer
| CRDF Stock | USD 2.61 0.07 2.76% |
Insider
Tod Smeal is Chief Officer of Cardiff Oncology
| Age | 59 |
| Phone | 858 952 7570 |
| Web | https://www.cardiffoncology.com |
Tod Smeal Latest Insider Activity
Tracking and analyzing the buying and selling activities of Tod Smeal against Cardiff Oncology stock is an integral part of due diligence when investing in Cardiff Oncology. Tod Smeal insider activity provides valuable insight into whether Cardiff Oncology is net buyers or sellers over its current business cycle. Note, Cardiff Oncology insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cardiff Oncology'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Tod Smeal over a year ago Acquisition by Tod Smeal of 167088 shares of Cardiff Oncology subject to Rule 16b-3 |
Cardiff Oncology Management Efficiency
The company has return on total asset (ROA) of (0.3833) % which means that it has lost $0.3833 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6757) %, meaning that it created substantial loss on money invested by shareholders. Cardiff Oncology's management efficiency ratios could be used to measure how well Cardiff Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Barbara Wood | Sellas Life Sciences | 61 | |
| Brent Rice | Autolus Therapeutics | 58 | |
| Jacquelyn JD | Cullinan Oncology LLC | 46 | |
| Chad MBA | NLS Pharmaceutics AG | N/A | |
| iur LLM | NLS Pharmaceutics AG | 58 | |
| Robert Dudley | Transcode Therapeutics | 73 | |
| Matthew CPA | PDS Biotechnology Corp | 55 | |
| Kenneth MD | Cue Biopharma | 64 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 52 | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| Edgar MD | Bolt Biotherapeutics | 78 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Lucinda Crabtree | Autolus Therapeutics | N/A | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| Kenneth LaMontagne | In8bio Inc | N/A | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| Karen Bergman | Bolt Biotherapeutics | N/A | |
| Kate Rochlin | In8bio Inc | 42 | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.38 |
Cardiff Oncology Leadership Team
Elected by the shareholders, the Cardiff Oncology's board of directors comprises two types of representatives: Cardiff Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cardiff. The board's role is to monitor Cardiff Oncology's management team and ensure that shareholders' interests are well served. Cardiff Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cardiff Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Levine, Chief Officer | ||
| Mark Erlander, CEO Director | ||
| Vicki Kelemen, Chief Officer | ||
| Tod Smeal, Chief Officer | ||
| Brigitte Lindsay, Senior Finance | ||
| MD FACP, Chief Officer | ||
| Charles RPh, Senior Affairs | ||
| Elizabeth Anderson, VP Administration |
Cardiff Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cardiff Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.68 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (76.37) % | ||||
| Current Valuation | 77.48 M | ||||
| Shares Outstanding | 51.13 M | ||||
| Shares Owned By Insiders | 6.60 % | ||||
| Shares Owned By Institutions | 25.97 % | ||||
| Number Of Shares Shorted | 7.72 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 2.70 X |
Currently Active Assets on Macroaxis
When determining whether Cardiff Oncology is a strong investment it is important to analyze Cardiff Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiff Oncology's future performance. For an informed investment choice regarding Cardiff Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiff Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiff Oncology. If investors know Cardiff will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiff Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cardiff Oncology is measured differently than its book value, which is the value of Cardiff that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiff Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cardiff Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiff Oncology's market value can be influenced by many factors that don't directly affect Cardiff Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiff Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiff Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiff Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.